Here is some of what you may have missed from the world's largest cancer research meeting.
Adam Feuerstein/STAT
By Adam Feuerstein, Matthew Herper, Angus Chen, and Katherine MacPhail
June 1, 2026
Adam Feuerstein
adam.feuerstein@statnews.com
ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
Research Presented by The US Oncology Network Demonstrates How Community Practices Are Expanding Patient Access Through APP‑Led Models at ASCO 2026
Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more
How HER2 biology is shaping next-generation cancer treatment
Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
Women authorship ‘still low’ in phase 3 trials at ASCO, but gains made
Pharma urged to modernize patient support as young adult cancer rates rise
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting.…
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Here's what to watch for at ASCO, cancer research's big meeting, in Chicago.
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck,…
